Tyrosine Kinase Inhibitors Noncompetitively Inhibit MCT8-Mediated Iodothyronine Transport | Zendy

Doreen Braun | Zendy; Theo D. Kim | Zendy; Philipp le Coutre | Zendy; Josef Köhrle | Zendy; Jerome M. Hershman | Zendy; Ulrich Schweizer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tyrosine Kinase Inhibitors Noncompetitively Inhibit MCT8-Mediated Iodothyronine Transport

Author(s) -

Doreen Braun,

Theo D. Kim,

Philipp le Coutre,

Josef Köhrle,

Jerome M. Hershman,

Ulrich Schweizer

Publication year - 2011

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-1837

Subject(s) - dasatinib , bosutinib , endocrinology , monocarboxylate transporter , medicine , nilotinib , organic cation transport proteins , tyrosine kinase inhibitor , sunitinib , tyrosine kinase , chemistry , imatinib , pharmacology , transporter , cancer , biochemistry , receptor , gene , myeloid leukemia

Tyrosine kinase inhibitors (TKI) are used for the treatment of various cancers. Case reports and clinical trials have reported abnormal thyroid function tests (TFT) after treatment with sunitinib, imatinib, sorafenib, dasatinib, and nilotinib. An increased requirement for levothyroxine was reported in thyroidectomized patients during TKI treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research